Product
Sofosbuvir
Aliases
GS-7977, PSI-7977, Sovaldi®
Name
Sovaldi
INN Name
SOFOSBUVIR
FDA Approved
Yes
5 clinical trials
1 organization
4 indications
1 document
Indication
Hepatitis C Virus InfectionIndication
Hepatitis CIndication
Liver CancerIndication
CirrhosisClinical trial
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsStatus: Terminated, Estimated PCD: 2023-01-06
Clinical trial
A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C InfectionStatus: Terminated, Estimated PCD: 2021-12-31
Clinical trial
Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C CirrhosisStatus: Completed, Estimated PCD: 2018-12-01
Clinical trial
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and RibavirinStatus: Completed, Estimated PCD: 2016-04-01
Document
DailyMed Label: SovaldiOrganization
Gilead Sciences, Inc.